Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Ayscough, Steve Trevisan, Francis Collins, Eric Lander, Craig Venter

Premium

Inpharmatica has bolstered the discovery side of its hybrid bioinformatics/drug discovery business model by appointing Andrew Ayscough as director of chemistry. Ayscough was previously director of research at British Biotech Pharmaceuticals. The company has also recruited a team of seven medicinal chemists from Millennium Pharmaceuticals.


Steve Trevisan, executive vice president and a director of Gene Logic, will step down, but will continue “in an advisory capacity” until the end of the year, the company said. Trevisan joined Gene Logic in April as part of its acquisition of Therimmune Research, where he was president and CEO.


Thomson ISI has named Francis Collins, Eric Lander, and Craig Venter among its 2003 Citation Laureates — authors of the most frequently cited papers as measured by ISI’s Citation Indexing process and therefore “potential Nobel Prize winners in 2003, or after,” according to the company. The 2003 Nobel Prizes will be announced on Oct. 6.

 

Filed under

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.